Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 16, 2021
Psychological well-being in cancer outpatients during COVID-19Daniela Bafunno, Francesca Romito, Fulvia Lagattolla, et al.
Clinical Lung Cancer|April 5, 2020
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With ImmunotherapyArsela Prelaj, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 29, 2020
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%Giulio Metro, Giuseppe Luigi Banna, Diego Signorelli, et al.
Clinical Lung Cancer|November 9, 2020
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab MonotherapyGiannis Mountzios, Alessandro de Toma, Panagiota Economopoulou, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Cancers|October 28, 2023
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and SurvivalKhalil Choucair, Caroline Nebhan, Alessio Cortellini, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas databaseClaudio Sini, Alessandro Russo, Diego Cortinovis, et al.
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Pageof 4